Vizsgálati helyszín
Changzhou No 2 Peoples Hospital
Changzhou, 213004, KínaMég nincs intézményhez kötve
- 19futó vizsgálat
- 2lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 21 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis13 vizsgálat
- 2. fázis4 vizsgálat
- 2/3. fázis2 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz12 vizsgálat
- Toboroz7 vizsgálat
- Lezárult2 vizsgálat
- Fő szponzor
- Janssen Research & Development, LLC20 vizsgálat
- Xian-Janssen Pharmaceutical Ltd.1 vizsgálat
Futó vizsgálatok
Toboroz
A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma
NCT07746687· 2. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
NCT07321873· 2. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis
NCT07302360· Xian-Janssen Pharmaceutical Ltd.· Forrás
Toboroz
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek